

## About


The Nu-Med Plus mission is to design, develop and market new patented technologies in the medical field, along with building key intellectual assets. Our strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its' technological expertise.

Our initial market focus is on medical applications for Nitric Oxide (NO). NO is a naturally-occurring molecule, widely recognized for its' importance in a number of biological processes. NO has the potential for treating diseases ranging from malaria to neonatal hypertension. Nu-Med Plus has developed inhaled nitric oxide products for use in hospital settings as well as for longer term applications outside hospital surroundings. Our product candidates are designed to deliver NO safely for a variety of therapeutic indications to clinicians and other end users. Nu-Med Plus will provide solutions that are less expensive and more user-friendly. In addition, the company has designed a NO delivery system that is lightweight and portable. Nu-Med Plus' medical devices deliver cost effective inhaled Nitric Oxide to patients in a manner unique to the market.\*

\* Nu-Med's Nitric Oxide delivery systems are investigational and limited by federal law to investigational use only. Our units will require testing and FDA approval prior to any commercial use.

## What is Nitric Oxide?

Nitric Oxide was named chemical of the year in 1992 by the Journal of Science. It is an important biological regulator and fundamental molecule in the fields of pulmonary medicine, cardiology, neuroscience, physiology and immunology. In 1998, the Nobel Prize in Medicine was awarded for discoveries concerning NO as a signaling molecule in the cardiovascular system.



Inhaled Nitric Oxide is presently used to treat thousands of patients per year in the United States, including term infants with pulmonary hypertension and some pre-term infants with respiratory insufficiency. Inhaled Nitric Oxide is a potent, pulmonary specific vasodilator that dilates blood vessels.

Numerous academic sponsored clinical trials have demonstrated the clinical utility of NO and potential uses for NO in an extensive variety of diseases and health complications, including: antibacterial, antiviral maladies; inflammatory disorders; head trauma; erectile dysfunction; pain and neuroprotection.

Nu-Med believes there is a significant marketplace for its' inhaled NO medical therapies. Currently available NO delivery systems are a concern for hospitals due to usage, tracking, storage and the necessity of returning empty compressed gas tanks. In addition, existing systems are large and awkward to use, impairing patient mobility within the hospital, and making inhaled Nitric Oxide outside the hospital environment nearly impossible. Nu-Med's planned NO delivery systems are expected to be smaller, more portable and easier to use, and available at significantly lower price points than systems currently available.

## Products

### 1. Low cost Nitric Oxide Hospital/Clinical Generator and Delivery System



Our team has developed a NO gas generating system that delivers a continuous intra-breath concentration of therapeutic NO to medically supervised patients who

are on ventilators in the hospital setting. The NO generating system is intended to be innovative and instinctive, along with being low cost. Currently, competitors offer single, 72-hour treatment for approximately \$9,000.

### 2. Mobile rechargeable Nitric Oxide Delivery System

Nu-Med has also developed a lightweight, portable NO delivery system that can be worn comfortably by patients within hospitals, allowing mobility between critical care units. This system may also be practical outside of the hospital setting for underserved chronic therapies, as well as for applications in developing nations. The product has the capability to deliver high purity NO to the patient at prescribed intervals, or 24 hours per day at controlled doses, by means of a nasal cannula or a face mask. Battery management will be controlled with a recharging capability from wall outlets, or from a back-up battery.



### 3. Delivery mask to maintain pure Nitric Oxide to patient

When mixed with oxygen, Nitric Oxide can cause a patient to have serious side effects. Existing systems designed to remove oxygen from the Nitric Oxide delivery path are extremely complicated and require extensive amounts of equipment. Nu-Med Plus is developing a patentable process which, simply and effectively, removes all oxygen from the Nitric Oxide being delivered to the patient through the use of a special delivery mask which filters out all toxic substances. This mask would eliminate the need for expensive machines to monitor Nitric Oxide levels during delivery to the patient.

## Markets

### 1. Neonatal Respiratory Problems - 1.3 Million cases/year

About one third of all new born infant deaths are related to respiratory complications. Nitric Oxide is currently being used to cure these problems in infants with a high degree of success. However, treatments generally cost about \$125 per hour and usually last about 72 hours. Due to the high cost, the use of Nitric Oxide in this market is prohibitive. Nu-Med Plus is developing a cost effective way to produce and transmit Nitric Oxide.

### 2. COPD- 80 Million cases/year

A disease of the lungs that is the third leading cause of death in the U.S. and the fourth leading cause of death worldwide. Inhaled NO appears effective in treating conditions that result in pulmonary hypertension, such as COPD.

### 3. Malaria- 8 Million cases/year

Malaria is transmitted through mosquitoes to humans and is most prevalent in Africa. There is currently no known cure. Most malaria survivors develop severe respiratory problems. Because of its' systemic anti-inflammatory properties, inhaled NO may potentially be used as adjuvant therapy for children with severe malaria to "buy time" for chemical antiparasite therapy to lower the parasite load.

### 4. Tuberculosis - 8 Million cases/year

Lethal infectious disease that attacks the lungs of the person infected. Nitric Oxide has been used in trials and has shown promising results to cure the disease.

### 5. ARDS- 2.2 Million cases/year

Severe lung syndrome with no known cure. Inhaled Nitric Oxide reduces the vascular resistance of open alveoli, offering a potentially beneficial effect on arterial oxygenation.

### 6. Chronic Wound Healing-6.5 million cases/year (USA)

The burden of treating chronic wounds is growing rapidly due to increasing health care costs, an aging population and, in the United States and beyond, a sharp rise in the incidence of diabetes and obesity worldwide. The specific benefits of NO in wound healing are associated with vasodilation, anti-microbial and anti-inflammatory properties.



## Management Team

### Jeff Robins – CEO-Chairman of the Board

Mr. Robins has 30 years of senior management experience in high technology companies coupled with 15 years of engineering leadership. He has extensive global experience including Operations Senior Director at Fujitsu Microelectronics. He has held various management positions at Intel and AMD. Mr. Robins holds degrees in Pharmacy and Political Science.

### Bill Moon - VP of Technology-Board of Directors

Mr. Moon's background includes positions of Principle Engineer and VP of Engineering at Quantum Corporation, the world's largest disk drive company, where he was instrumental in growing the company to over 10,000 employees. Mr. Moon has a M.S. and B.S. in Mechanical Engineering. He holds numerous patents in the high technology sector.

### Craig Morrison M.D -VP of Research-Board of Directors

Dr. Morrison has been an attending and consulting staff general surgeon since 1978. He received his Doctor of Medicine Degree from the University of Oregon Medical School. Dr. Morrison is a practicing surgeon in the State of Utah.

### Thomas Tait –VP of Scientific Development-Board of Directors

Tom Tait co-founded ChiraTech Inc., a high technology Company that was sold to Thermo Electron Corporation. Mr. Tait holds an MBA in Technology Management and a B.S. in Chemistry from Clarkson University. He also holds numerous patents in Optics and MEMS technologies.

### Brett Earl M.D. - VP of Medical Marketing-Board of Directors

Dr. Earl is a Board Certified Emergency Physician with over 15 years of experience in his field, He has been published numerous times and serves on various Medical Boards in Utah. After practicing Emergency Medicine for 15 years, he opted to study and practice Functional Medicine. Dr. Earl currently practices Functional Medicine in Bountiful, Utah. Dr. Earl received his Medical Degree from the University of Nevada, Reno.

### Mark Christensen- Chief Financial Officer

Mr. Christensen has been an active licensed CPA for over 25 years. He has several years of experience with the international accounting firm, KPMG Peat Marwick and as a partner in Bushman, Miyasaki & Associates and Stewart & Christensen, LLC. He has provided services to a wide range of industries and businesses. Mr. Christensen graduated Cum Laude from the University of Utah and holds an M.Pr.A. in Accounting, a B.A. in Accounting, and a B.A. in Finance.

### Charles Ivester M.D. PH.D.-Medical Advisor

Dr. Ivester received his Ph.D. and M.D. from the Medical University of South Carolina and is board certified in Pulmonary Disease, Internal, Critical Care, and Sleep Medicine while holding licensure as a physician and surgeon in the State of Utah. He has participated in countless research ventures, been published numerous times while presenting his findings at a variety of national and international venues along with serving as an educator/teacher at a number of conferences and medical related schools.

### Corporate Office:

455 E. 500 S. Suite #205  
SLC, UT 84111

### Laboratory:

1266 S. 1380 W.  
Orem, UT 84058